Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Product Development, regulatory affairs chiefs, R&D directors, and commercial directors from saliva collection device manufacturers, diagnostic kit producers, and OEM suppliers. Demand-side sources included procurement leads from hospitals, diagnostic chains, and research institutions, as well as medical laboratory directors, clinical pathologists, diagnostic center managers, dental clinic practitioners, forensic laboratory directors, and pharmaceutical research scientists. Market segmentation was validated, product pipeline timelines were confirmed, and insights regarding clinical adoption patterns, pricing strategies, reimbursement dynamics, and point-of-care integration trends were obtained through primary research.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and diagnostic test volume analysis. The methodology included:
Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America
Product mapping across parotid gland collection devices, submandibular/sublingual collection systems, minor salivary glands collection tools, and other specialized collection technologies
Analysis of reported and modeled annual revenues specific to saliva collection and diagnostic portfolios
Coverage of manufacturers representing 70-75% of global market share in 2024
Extrapolation using bottom-up (test volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across disease diagnosis, forensics, and pharmaceutical/biotechnology applications
